Back To: Home : Featured Technology : Gene and Cell Therapies

CLICK HERE FOR WHAT'S NEW IN:
 

BCX4430 improves Ebola survival
October 2016
SHARING OPTIONS:

RESEARCH TRIANGLE PARK, N.C.—A proof-of-concept study of BioCryst Pharmaceuticals' broad-spectrum antiviral, BCX4430, for the delayed treatment of Ebola virus infection in rhesus macaques yielded positive results, the company noted early September. After the initial inoculation of virus on day zero, six of six animals survived after receiving 100 mg/kg BCX4430 twice on day two, followed by 25 mg/kg twice daily for nine days, compared to none of the six control animals. The animals treated with the same loading and maintenance dose regimen of BCX4430 starting on day three also saw improved survival (four of six, 67 percent), as did animals treated with 25 mg/kg of BCX4430 twice daily for 14 days starting on day two (four of six, 67 percent). This project is largely funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health and the Department of Health and Human Services and the Biomedical Advanced Research and Development Authority.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.